Using alemtuzumab in a lymphodepleting regimen should reduce a patient's host immune cells and improve allogeneic CAR T-cell expansion and persistence. UCART T cells are being evaluated for the treatment of relapsed/refractory acute lymphocytic leukemia and relapsed/refractory acute myeloid leukemia.

The companies agreed to execute a commercial supply of alemtuzumab, although financial details were not disclosed.

Sanofi, Stanford partner to study immunology
Sanofi has entered into a three-year research collaboration with the Stanford University School of Medicine to advance the understanding of immunology...

Sanofi to provide fill/finish services for Moderna COVID-19 vaccine
Moderna has inked a new agreement with Sanofi in order to scale up U.S. manufacturing capacity for its COVID-19 vaccine.

Sanofi acquires Tidal Therapeutics, expands vaccine manufacturing
Sanofi announced that it has purchased Tidal Therapeutics for $160 million and plans to expand its vaccine manufacturing capability through a site...

Sanofi to build new manufacturing facility in Toronto
Sanofi announced an investment of approximately $737 million U.S. in a new vaccine manufacturing facility at its existing site in Toronto, Canada,...

Cytovia, Cellectis partner on gene-edited NK cells
Cytovia Therapeutics and Cellectis have entered into a strategic research and development collaboration to develop gene-edited natural killer (NK) and...